ERBB2 and cancer: This study clearly demonstrated that the combination of NIR-PIT using the HER2 Affibody-IR700Dye conjugate and the trastuzumab-IR700Dye conjugate represents a new treatment strategy for heterogeneous HER2-positive cancer, including HER2 low-expressing cancer, trastuzumab-resistant cancer, and brain metastasis.